Press Release
The Ivy Brain Tumor Center Announces the Expansion of the Leadership Team with Charuta Furey, MD
The Ivy Brain Tumor Center is pleased to welcome Charuta Furey, MD, to its team as Assistant Professor of Neurosurgery, Pharmacogenomics Core Leader, and Principal Investigator. Dr. Furey earned her bachelor’s degree from Harvard College and her medical degree from Yale University School of Medicine before completing her seven-year neurological surgery residency at Barrow Neurological Institute, where she trained under Nader Sanai, MD.
Ivy Brain Tumor Center Announces Completion of Enrollment in Phase 3 Gliofocus Study for Patients with Newly-Diagnosed Glioblastoma
The Ivy Brain Tumor Center at Barrow Neurological Institute today announced completion of randomization in the landmark Phase 3 Gliofocus study, a global trial evaluating niraparib versus standard-of-care temozolomide in adults with newly diagnosed, MGMT-unmethylated glioblastoma (GBM).
Support Brain Cancer Research
May is Brain Tumor Awareness Month, and Barrow Neurological Foundation is ramping up its efforts to raise funds for cutting-edge research at...
Advancing Brain Tumor Research: A New Phase 0/1 clinical trial at the Ivy Brain Tumor Center
The Ivy Brain Tumor Center announces the activation of a new clinical trial evaluating a B7-H3-targeted antibody-drug conjugate (ADC), risvutatug rezetecan (Ris-Rez), in recurrent grade 4 glioma and brain metastases. Ris-Rez is designed to deliver a therapeutic payload to tumor cells that express B7-H3.
2026 Barrow Grand Ball Ball Raises $5.1 Million for Brain Cancer Research
An impressive $5.1 million was raised specifically through the Ball to help advance critical research at the Ivy Center.
Phase 3 Gliofocus Study Drug, Niraparib, Granted Orphan Drug Designation by U.S. FDA for Treatment of Malignant Glioma, including Glioblastoma
The U.S. FDA has granted ODD to niraparib for the treatment of malignant glioma, including GBM. The designation is supported...
Ivy Brain Tumor Center Expands Global Phase 3 Gliofocus Study to the EU and Additional U.S. States
The Ivy Brain Tumor Center at Barrow Neurological Institute has announced the expansion of the Gliofocus Study, activating two new sites in Europe and two additional locations in the United States. The newly activated sites include Groupe Hospitalier Pitié-Salpêtrière in Paris, France; Hospital Universitario 12 de Octubre in Madrid, Spain; The NeuroMedical Center Clinic in Baton Rouge, Louisiana; and UC San Diego Moores Cancer Center in La Jolla, California. The Gliofocus Study is an open-label, randomized Phase 3 trial (NCT06388733) that will compare the efficacy of niraparib, a PARP1/2 selective inhibitor, to temozolomide head-to-head in adult patients with newly diagnosed MGMT-unmethylated glioblastoma.
Ivy Brain Tumor Center to Present Multiple Abstracts and a Special Session on Innovative Clinical Trial Design at the 2024 European Association of Neuro-Oncology Annual Meeting
The Ivy Brain Tumor Center at Barrow Neurological Institute will present updated study results and a special session on clinical trial design at the 19th Meeting of the European Association of Neuro-Oncology (EANO), which will take place in Glasgow, Scotland, October 17-20, 2024.
Ivy Brain Tumor Center’s Dr. Nader Sanai Named Arizona Bioscience Researcher of the Year
Dr. Nader Sanai, Director of the Ivy Brain Tumor Center, has been named the 2024 Arizona Bioscience Researcher of the Year by the Arizona Bioindustry Association. This prestigious honor recognizes Dr. Sanai's pioneering efforts and unwavering dedication to advancing new therapies for brain tumor patients, breaking new ground in the fight against this challenging disease.
First patient dosed in Phase 3 Gliofocus Study for newly diagnosed glioblastoma patients at the Ivy Brain Tumor Center
The Ivy Brain Tumor Center announced that the first patient has been dosed in the pivotal Phase 3 Gliofocus Study. Gliofocus is an open-label, randomized Phase 3 trial that will compare the efficacy of niraparib, a PARP1/2 selective inhibitor, to temozolomide head-to-head in adult patients with newly diagnosed MGMT-unmethylated glioblastoma.